NetraMark HoldingsAINMF +7.48%31 3-Year ROIIC % is -28.83 as of Sep. 2025. GuruFocus rates AINMF with a GF Score™ of 31/100 and a GF Value™ of $0.21 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 621 Healthcare Providers & Services companies, NetraMark Holdings ranks worse than 80.19% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
NetraMark Holdings's 3-Year ROIIC % for the quarter that ended in Sep. 2025 was -28.83%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for NetraMark Holdings's 3-Year ROIIC % or its related term are showing as below:
AINMF's 3-Year ROIIC % is ranked worse than 80.19% of 621
companies
in the Healthcare Providers & Services industry
Industry Median: 3.46
vs AINMF: -28.83
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
NetraMark Holdings 3-Year ROIIC % Related Terms
NetraMark Holdings 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for NetraMark Holdings's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AINMF vs VEEV, BTSG, TEM: 3-Year ROIIC % Comparison
For the Health Information Services subindustry, NetraMark Holdings's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NetraMark Holdings 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NetraMark Holdings's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where NetraMark Holdings's 3-Year ROIIC % falls into.
NetraMark Holdings's 3-Year ROIIC % for the quarter that ended in Sep. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -3.774 (Sep. 2025) - -5.8383774 (Sep. 2022) )
/
( 0.028 (Sep. 2025) - 6.705 (Sep. 2022) )
=
2.0643774
/
-6.677
=
-30.92%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
NetraMark Holdings (AINMF) has a 3-Year ROIIC % of -28.83 as of Sep. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on NetraMark Holdings and its competitors. According to the industry distribution chart, NetraMark Holdings ranks #498 out of 621 companies in the Healthcare Providers & Services industry, placing it in the top 80.2%.
Is NetraMark Holdings' 3-Year ROIIC % too high?
NetraMark Holdings' current 3-Year ROIIC % is -28.83. Based on the distribution chart, NetraMark Holdings ranks #498 out of 621 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, NetraMark Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NetraMark Holdings' 3-Year ROIIC % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, NetraMark Holdings ranks #498 out of 621 companies for 3-Year ROIIC %. This places NetraMark Holdings in the lower half of its industry. The industry median 3-Year ROIIC % is 3.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.46, based on 621 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on NetraMark Holdings and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NetraMark Holdings's current 3-Year ROIIC % is -28.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NetraMark Holdings stock overvalued right now?
Based on GuruFocus' analysis, NetraMark Holdings (AINMF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.21, compared to a current price of $0.65 — trading 208.5% above its estimated fair value. The current 3-Year ROIIC % is -28.83. NetraMark Holdings' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For NetraMark Holdings (AINMF), the current 3-Year ROIIC % is -28.83 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NetraMark Holdings (AINMF) Overvalued in 2026?
Based on GuruFocus' analysis, NetraMark Holdings stock appears to be overvalued.
The current stock price of $0.65 is trading 208.5% above its estimated GF Value™ of $0.21.
GuruFocus considers NetraMark Holdings to be Significantly Overvalued.
Key valuation signals for AINMF:
3-Year ROIIC %: -28.83
GF Value™: $0.21 vs. price of $0.65 (208.5% above fair value)
No single metric tells the full story. See the AINMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NetraMark Holdings Inc provides AI-powered insights and software solutions to optimize clinical trial design and outcomes for pharmaceutical sponsors. The company offers AI solutions to trial sponsors, CROs, and biotechnology companies across the globe. It earns revenue from its proprietary NetraAI platform, an advanced machine learning system purpose-built to analyze complex clinical trial data and identify meaningful patient subpopulations.
31GF Score
Get the complete analysis for AINMF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AINMF has been successfully added to your 
